ArticleFrontiers in neurology
Pre-treatment structural brain biomarkers predict response to repetitive transcranial magnetic stimulation in subjective tinnitus.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Variable efficacy of repetitive transcranial magnetic stimulation (rTMS) for tinnitus necessitates predictive biomarkers. Pre-treatment brain structural features may predict rTMS outcomes, given that tinnitus involves structural brain alterations and rTMS can induce neuroplastic changes. Objective: To identify pre-treatment brain structural biomarkers predictive of rTMS efficacy in subjective tinnitus. Methods: We prospectively enrolled 64 patients with subjective tinnitus and 18 healthy controls (HCs). Patients underwent a 2-week course of rTMS. High-resolution T1-weighted structural MRI (sMRI) was acquired, and 242 whole-brain morphometric features were extracted. Univariate analysis identified features differing between responders and non-responders, which subsequently were used to construct a machine learning model evaluated via 5-fold cross-validation and SHapley Additive exPlanations (SHAP) analysis. Feature significance was further interpreted through three-group comparisons among responders, non-responders, and HCs. Spearman correlation analyses were performed between structural features and clinical improvement scores (ΔVAS, ΔTHI) as well as baseline clinical measures. Results: Thirty-six patients (56.25%) were classified as responders. Ten regional features distinguished responders from non-responders, encompassing prefrontal, limbic, sensorimotor, and parietal networks. The predictive model (ExtraTreesGini_BAG_L1) achieved optimal performance (AUC = 0.85; accuracy = 0.77; precision = 0.71; recall = 0.97; F1-score = 0.82). SHAP analysis identified right pars triangularis of the inferior frontal gyrus (IFGtriang-R) gray matter volume (GMV) as the top predictor (positive influence). Three-group comparison revealed that IFGtriang-R GMV was significantly larger in responders (0.90 ± 0.08) than in both HCs (0.86 ± 0.06) and non-responders (0.86 ± 0.07), indicating a specific structural signature associated with positive treatment outcome. Spearman correlation analyses revealed that IFGtriang-R volume did not significantly correlate with ΔVAS or ΔTHI, and no structural feature showed a robust association with baseline clinical measures after Bonferroni correction. Conclusion: Responders were characterized by relative enlargement of the IFGtriang-R, suggesting a threshold effect of neuroplastic reserve conducive to rTMS efficacy. Pre-treatment sMRI assessment of this region may facilitate patient stratification for rTMS treatment, advancing precision neuromodulation for tinnitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.